Chaturvedi Shalini, Farmer Takeisha, Kapke Gordon F
Department of Biomarker Services, Covance Central Laboratory Services Inc., 8211 SciCor Drive, Indianapolis, Indiana 46214-2985, USA.
Int J Biol Sci. 2009;5(2):128-34. doi: 10.7150/ijbs.5.128. Epub 2009 Jan 19.
Urinary kidney injury molecule (KIM-1) is a sensitive quantitative biomarker for early detection of kidney tubular injury. The objective of the present work was to analytically validate this urinary renal injury biomarker. Duo-set reagents from R&D were used to develop the ELISA and validate the assay's linearity, intra-run precision, inter-run precision, lower limit of quantification, recovery, dilutional verification, reference range, stability, and length of run. The reference range data suggests that the healthy population falls within the assay range (59 - 2146 pg/mL) and upper limit of quantitation for this assay is 17168 pg/mL for the patient population. This is a robust assay to detect urinary levels of KIM-1, which serves as a non-invasive sensitive, reproducible, and potentially high-throughput method to detect early kidney injury in drug development studies.
尿肾损伤分子(KIM-1)是早期检测肾小管损伤的一种敏感定量生物标志物。本研究的目的是对这种尿肾损伤生物标志物进行分析验证。使用研发公司的双试剂盒试剂开发酶联免疫吸附测定(ELISA),并验证该检测方法的线性、批内精密度、批间精密度、定量下限、回收率、稀释验证、参考范围、稳定性和检测时长。参考范围数据表明,健康人群的数值在检测范围内(59 - 2146 pg/mL),该检测方法对患者群体的定量上限为17168 pg/mL。这是一种检测尿KIM-1水平的可靠检测方法,在药物研发研究中,它是一种用于检测早期肾损伤的非侵入性、敏感、可重复且可能高通量的方法。